What is SOTIO?
SOTIO is a biotechnology firm dedicated to advancing cancer treatment through a robust pipeline of immunotherapies. The company focuses on developing safer and more effective treatments for various solid tumor types, utilizing internally developed and in-licensed candidates. Their approach emphasizes immunocytokines, cell therapies, and antibody-drug conjugates, aiming to translate cutting-edge science into tangible patient benefits. SOTIO actively seeks to expand its portfolio with promising oncology projects, particularly those in advanced stages of development.
How much funding has SOTIO raised?
SOTIO has raised a total of $316.5M across 1 funding round:
Other Financing Round
$316.5M
Other Financing Round (2021): $316.5M with participation from PPF Group
Key Investors in SOTIO
PPF Group
PPF Group is an international financial and investment group with a diverse portfolio spanning financial services, telecommunications, biotechnology, and real estate. Their investment in SOTIO suggests a strategic interest in the biotechnology and healthcare sectors.
What's next for SOTIO?
The substantial enterprise-level funding indicates SOTIO is poised for significant scaling and further clinical development. This capital injection will likely accelerate the progression of their diverse pipeline, potentially leading to expanded clinical trials and the advancement of novel cancer therapies toward market approval. The company's strategic focus on solid tumors and its commitment to innovative immunotherapies position it for continued growth and impact in the oncology landscape.
See full SOTIO company page
